OHE has just published two new briefings entitled ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?’. Both publications are reports of panel sessions held at the HTAi 2016 meeting in Tokyo.
Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled "New Age Decision Making in HTA: Is It Applicable in Asia?". To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic.
Responses on subjective scales (like the EQ-5D) will be inaccurate if groups systematically differ in their use and/or interpretation of the categories. Anchoring vignettes offer a promising solution to reporting heterogeneity.
OHE is pleased to be working with four MSc students this year. The students, from City University and the London School of Economics, will spend three months at OHE being supervised and trained by various members of the OHE team whilst completing their MSc theses.
OHE is set to work on seven new projects funded by the EuroQol Research Foundation. The work will cover a range of topics from understanding the aspects of health that are important to people, to analysing the distribution of EQ-5D observations, to exploring the appropriateness of the EQ‐5D questionnaire in Asian populations.
On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology Initiative (POI) as part of a wider research project being undertaken by OHE.
The Association of the British Pharmaceutical Industry, in conjunction with the Office of Health Economics, invites you to register for a webinar on Monday 18th July: New EQ-5D-5L value sets for England and the UK and implications for HTA.
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.